Health ❯ Healthcare ❯ Pharmaceuticals

Drug Regulation

FDA FDA Actions Mifepristone FDA Decisions Counterfeit Drugs Counterfeit Medications Compounding Pharmacies GLP-1 Drugs Anvisa Peptides

Vitruvias Recalls Lot of Thyroid Tablets Over 'Superpotent' Test Results

Testing showed Lot 504950 may deliver excess thyroid hormone, so the company has withdrawn the batch and is notifying distributors for destruction.

Anvisa Approves First Brazil-Made Generic Semaglutide and a Similar Product

Mounjaro Study Finds Lower Heart‑Attack Risk as UK Safety Reports Rise

Anvisa Orders Seizure of Specific Falsified Mounjaro Units

FDA Advisory Panel Recommends Six Peptides for Pharmacy Compounding

Anvisa Says Retatrutida Is Unapproved as Illegal Versions Spread

FDA Advisers Narrowly Recommend Allowing Six Unapproved Peptides for Compounding

U.S. Recall Of Cetirizine Tablets After Ranitidine Contamination Detected

Anvisa Seizes Falsified Mounjaro Lots and Bans Unregistered Supplements

Regulators Move to Strip Approval of Tavneos After Trial Misconduct and Liver Safety Signals

India Cancels Licences After Spurious Oxytocin Batch Linked to Maternal Deaths

EMA Committee Recommends Revoking Tavneos Authorization

India Bans 16 Fixed‑Dose Combination Drugs

Pakistan Approves Nationwide Digital Track-and-Trace System for Medicines

Anvisa Suspends Enalapril and Halaven Lots After Manufacturers Report Quality and Labeling Faults

Rajasthan Bans TOCIN Oxytocin After Sample Shows No Active Ingredient

India Reclassifies Pregabalin as Schedule H1

Anvisa Halts Specific Lots of Cimed Statins and Hypofarma Dexamethasone

Kissei Discloses 20 Deaths in Japan Among Tabneous Users

FDA Names Mike Davis Acting Drug Chief as Tracy Beth Høeg Exits